Savoy Pharmaceuticals
Salt Lake City, Utah, United States
About Savoy Pharmaceuticals
Savoy Pharmaceuticals develops innovative products to treat, heal, and improve the quality of life for patients in the fields of oncology and virology. The company’s first product is a unique treatment targeted to a protein found on the surface of Hepatitis C (HCV) infected liver cells, HIV infected cells, and Hepatocellular carcinoma (liver cancer). Savoy’s technology is based on the company’s revolutionary discovery that TK1 is expressed on HCV-infected cells, HIV infected cells, and liver cancers, and is not found on the surface of any normal cell type. The company has developed a fully human monoclonal antibody that binds specifically to TK1 on the surface of liver cancer directly attributable to the Hepatitis C Virus, HCV, infected cells, HCV and HIV co-infected cells (HCV/HIV). The company has performed the preclinical testing required to demonstrate that our antibody binds to and kills cancerous cells while causing no harm to any normal cells or tissues in the body. This is a breakthrough in the war against cancer and opens the door to unique therapeutic applications using the antibody.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $2.5M
- Funding stage: Seed
- Last round: Angel (Jan 2014)
- Website: savoypharmaceuticals.com
- Phone: +1 801-990-3133
Industries & Categories
Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/savoy-pharmaceuticals-2550597 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.